Cresco Labs Inc. (OTCMKTS:CRLBF) Receives $2.50 Average Target Price from Analysts

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $2.50.

A number of brokerages recently issued reports on CRLBF. Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research report on Monday, November 11th. Roth Capital upgraded shares of Cresco Labs to a “strong-buy” rating in a research note on Sunday, November 10th. Finally, Atb Cap Markets downgraded shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th.

Cresco Labs Trading Up 0.2 %

Shares of CRLBF stock opened at $0.88 on Wednesday. Cresco Labs has a 1 year low of $0.78 and a 1 year high of $2.60. The firm’s fifty day simple moving average is $0.91 and its 200 day simple moving average is $1.28. The firm has a market capitalization of $430.30 million, a P/E ratio of -4.41 and a beta of 1.79. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.